KMO and Parkinson disease: Treatment with the Ro 61-8048 and other KMO inhibitors, such as UPF648 and CHDI-340246, was effective in relieving neurological symptoms in the animal models of AD, HD, PD, and depression [55,162,163,209,210,211,212,213,214,215,216,217].